Does the location of meningioma have any impact on postoperative outcomes? – A prospective cohort study

Meningioma is a CNS tumour with a moderate growth rate that arises from the meninges. (1) Meningiomas are produced by arachnoid cells that are situated on the inner surface of the dura. Meningiomas are the most common primary CNS tumour, accounting for about 36% of cases and 53% of nonmalignant CNS tumours, with an incidence of 7.86 cases per 100,000 people each year (2, 3). In addition to symptoms from the mass effect of the central nervous system, such as headache, patients with meningiomas also experience a variety of neurologic symptoms brought on by the compression of surrounding central nervous system components. As a result, the type of symptoms is directly influenced by the tumour's location. Meningiomas can develop in places where there are arachnoid cells, and their locations range from the para-sagittal region to the spine. (4, 5). The management decisions depend on the particular characteristics of each area(6). For instance, patients with convexity meningiomas are more likely to present with seizures as a baseline symptom compared to skull base meningiomas which result in a higher frequency of headaches, anosmia, ocular deficits, and auditory deficits(7). The surgical care of these tumours has changed to demonstrate better results and decrease mortality and surgical morbidity, but it is still linked to significant morbidity and problems. Microsurgical methods and surgical approaches to these tumours have also improved. (8) The purpose of this prospective study is to investigate how the anatomical location of meningioma affects the postoperative outcomes after its excision. Intriguing, in our opinion, is the analysis of the clinical outcomes of meningioma patients in a setting of developing countries.